Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.
Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particula...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/5415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841564374439821312 |
|---|---|
| author | Giovanni Manfredi Assanto , Matteo Totaro Poggiali Rebecca Delli Paoli Adele Annechini Giorgia D’Elia Gianna Maria Aji Francesco Petrucci Luigi Fazio Francesca Del Giudice Ilaria Martelli Maurizio Micozzi Alessandra Giuseppe Gentile |
| author_facet | Giovanni Manfredi Assanto , Matteo Totaro Poggiali Rebecca Delli Paoli Adele Annechini Giorgia D’Elia Gianna Maria Aji Francesco Petrucci Luigi Fazio Francesca Del Giudice Ilaria Martelli Maurizio Micozzi Alessandra Giuseppe Gentile |
| author_sort | Giovanni Manfredi Assanto , |
| collection | DOAJ |
| description |
Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, develop more often a symptomatic and a more serious disease of Covid-19. Various therapeutic and prophylactic agents are being used against COVID‐19 such as antiviral drugs, vaccines and antiviral S‐protein monoclonal antibodies. Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with B-cell malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies that bind SARS-CoV-2 spike protein and inhibits the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development. In the setting of hematology real-life, few data are available on the impact of pre-exposure prophylaxis, given the multiple factors involved in the clinical behavior of SARS-CoV-2 . Our aim was to evaluate the clinical benefit and the safety of this strategy at our center.
|
| format | Article |
| id | doaj-art-2333e79f73004c0eb7baff70540cfd15 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-2333e79f73004c0eb7baff70540cfd152025-01-02T22:45:55ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062023-10-0115110.4084/MJHID.2023.061Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.Giovanni Manfredi Assanto ,0Matteo Totaro Poggiali RebeccaDelli Paoli Adele1Annechini GiorgiaD’Elia Gianna MariaAji Francesco2Petrucci Luigi3Fazio Francesca4Del Giudice Ilaria5Martelli Maurizio6Micozzi AlessandraGiuseppe Gentile7Haematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeHaematology, Department of Translational and Precision Medicine, Sapienza University of RomeDepartment of Cellular Biotechnology and Hematology University La Sapienza, Rome. Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, develop more often a symptomatic and a more serious disease of Covid-19. Various therapeutic and prophylactic agents are being used against COVID‐19 such as antiviral drugs, vaccines and antiviral S‐protein monoclonal antibodies. Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with B-cell malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies that bind SARS-CoV-2 spike protein and inhibits the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development. In the setting of hematology real-life, few data are available on the impact of pre-exposure prophylaxis, given the multiple factors involved in the clinical behavior of SARS-CoV-2 . Our aim was to evaluate the clinical benefit and the safety of this strategy at our center. http://www.mjhid.org/index.php/mjhid/article/view/5415B-cell malignanciesCOVID-19tixagevimab-cilgavimabPre-exposure prophylaxis |
| spellingShingle | Giovanni Manfredi Assanto , Matteo Totaro Poggiali Rebecca Delli Paoli Adele Annechini Giorgia D’Elia Gianna Maria Aji Francesco Petrucci Luigi Fazio Francesca Del Giudice Ilaria Martelli Maurizio Micozzi Alessandra Giuseppe Gentile Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. Mediterranean Journal of Hematology and Infectious Diseases B-cell malignancies COVID-19 tixagevimab-cilgavimab Pre-exposure prophylaxis |
| title | Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. |
| title_full | Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. |
| title_fullStr | Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. |
| title_full_unstemmed | Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. |
| title_short | Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. |
| title_sort | impact of sars cov 2 prophylaxis with tixagevimab cilgavimab in high risk patients with b cell malignancies a single center retrospective study |
| topic | B-cell malignancies COVID-19 tixagevimab-cilgavimab Pre-exposure prophylaxis |
| url | http://www.mjhid.org/index.php/mjhid/article/view/5415 |
| work_keys_str_mv | AT giovannimanfrediassanto impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT matteototaro impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT poggialirebecca impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT dellipaoliadele impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT annechinigiorgia impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT deliagiannamaria impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT ajifrancesco impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT petrucciluigi impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT faziofrancesca impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT delgiudiceilaria impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT martellimaurizio impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT micozzialessandra impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT giuseppegentile impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy |